Clinical trials

Phase 2: Active, currently recruiting patients.
Australian sites: Sydney, Melbourne, Adelaide, Launceston

Ambroxol is a prescription cough medication that is predicted to slow ALS disease progression. 

Learn more about this trial

Phase 3: Active, currently recruiting patients.
Australian site: Gold Coast University Hospital, Queensland.

There are anecdotal reports of cannabis slowing disease progression in persons with MND and that cannabis may relieve symptoms of spasticity and pain.

Learn more about this trial

Active, currently recruiting patients. 
Australian sites: Adelaide, Brisbane, Melbourne, Perth, Sydney

This study will test whether specific and individualised treatment with non-invasive ventilation (NIV) in combination with a sleep study leads to better outcomes in people with MND

Learn more about this trial 

Phase 3:  Active and currently recruiting patients, however this trial is only open to people with a specific mutation in the unc13A gene
Australian sites: Sydney, Sunshine Coast, Brisbane, Adelaide, Melbourne, Perth

Previous studies have shown that Lithium Carbonate may be beneficial to some people with motor neurone disease. This trial is testing the effectiveness of lithium carbonate in patients who have a specific mutation in the unc13A gene.

Learn more about this trial  

Phase 3 (equivalent): Active and currently recruiting patients, however this trial is open only to people with a known SOD1 genetic mutation
Australian sites: Sydney

Please note that this study is open to those who are not yet showing symptoms of motor neurone disease, but who have a known mutation of the SOD1 gene. 

Learn more about this trial

Phase 1b: Completed, data currently being analysed. 

ALS-205 (also called PMX205), has been designed to interfere with how the body’s immune system attacks the brain. The drug works by inhibiting a molecule involved in inflammation. 

Learn more about this trial 

Phase 2/3: There are no Australian sites for this phase of the trial.  

Monepantel is a well-known veterinary drug. It is being trialed in MND patients as it has been shown to reduce protein aggregation in cells. The accumulation of abnormal protein within the motor neurons of the brain is associated with motor neurone disease.

Learn more about this trial 

Phase 2: Completed, data currently being analysed. 

About half of all patients with ALS experience a change in their energy use that causes their body to consume more energy. This process is known as hypermetabolism and accelerates the spreading of ALS throughout the body. Trimetazidine is thought to be able to slow down the hypermetabolism experienced in ALS patients.

Learn more about this trial

Phase 2: Recruitment for Phase 2 of this trial is now complete. 

The aim of the REAL Study (Rho-kinasE for Als Study) is to assess the preliminary safety and efficacy of BRAVYL in patients with ALS.  The open label study enrolled 20 patients at up to 10 sites and participants are receiving treatment with BRAVYL for 6 months.

Learn more about this trial. 

Phase 1: Recruitment for Phase 1 of this trial is now complete. 

SPG-302 has been developed to target the synapse in nerve cells. The synapse is the site of contact between two nerve cells or the nerve cell and muscle and enables communication via chemical signals. This communication is key for brain control of muscles for movement. One major aspect of MND is the loss of these synapses. SPG-302 has been designed to increase the number of synapses in nerve cells.

Learn more about this trial